Skip to main content

Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma

User login

Username

Password

Reset your password

Type	Lead	score